Figure 5 | Scientific Reports

Figure 5

From: The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

Figure 5

The association between ΔbTMB dynamics and clinical outcome of gastric cancer patients treated with nivolumab monotherapy. (a) Association between tumor response and changes of bTMB between pre- vs. on-treatment (immediately before the third cycle) samples. (b) Correlation between bTMB change from the baseline and degree of tumor shrinkage. (c) Comparison of disease control rate (DCR) between cases with decreased bTMB vs. non-decreased bTMB. Kaplan–Meier estimates of progression-free survival (PFS, d) and overall survival (OS, e) of patients with decreased- vs. non-decreased- bTMB. bTMB blood tumor mutation burden.

Back to article page